|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.17/0.60
|
企业价值
502.70M
|
资产负债 |
每股账面净值
0.24
|
现金流量 |
现金流量率
--
|
损益表 |
收益
2.07M
|
每股收益
0.07
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/21 08:38 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS,is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. |